DE60043391D1 - Verwendung von leptin mit einem vegf hemmer und/oder angiogenese hemmer zur hemmung der proliferation endothelialer zellen - Google Patents

Verwendung von leptin mit einem vegf hemmer und/oder angiogenese hemmer zur hemmung der proliferation endothelialer zellen

Info

Publication number
DE60043391D1
DE60043391D1 DE60043391T DE60043391T DE60043391D1 DE 60043391 D1 DE60043391 D1 DE 60043391D1 DE 60043391 T DE60043391 T DE 60043391T DE 60043391 T DE60043391 T DE 60043391T DE 60043391 D1 DE60043391 D1 DE 60043391D1
Authority
DE
Germany
Prior art keywords
hemmer
leptin
angiogenic
vegf
proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60043391T
Other languages
English (en)
Inventor
Menachem Rubinstein
Batya Cohen
Dalit Barkan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL13173999A external-priority patent/IL131739A0/xx
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of DE60043391D1 publication Critical patent/DE60043391D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60043391T 1999-09-05 2000-09-04 Verwendung von leptin mit einem vegf hemmer und/oder angiogenese hemmer zur hemmung der proliferation endothelialer zellen Expired - Lifetime DE60043391D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL13173999A IL131739A0 (en) 1999-09-05 1999-09-05 Use of leptin in inhibition of endothelial cell proliferation
IL13231299A IL132312A0 (en) 1999-09-05 1999-10-10 Use of leptin in inhibition of endothelial cell proliferation
PCT/IL2000/000525 WO2001018040A2 (en) 1999-09-05 2000-09-04 Use of leptin in inhibition of endothelial cell proliferation

Publications (1)

Publication Number Publication Date
DE60043391D1 true DE60043391D1 (de) 2010-01-07

Family

ID=26323878

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60043391T Expired - Lifetime DE60043391D1 (de) 1999-09-05 2000-09-04 Verwendung von leptin mit einem vegf hemmer und/oder angiogenese hemmer zur hemmung der proliferation endothelialer zellen

Country Status (19)

Country Link
EP (1) EP1210108B1 (de)
JP (1) JP2003508544A (de)
KR (1) KR100683362B1 (de)
CN (1) CN1189479C (de)
AR (1) AR025494A1 (de)
AT (1) ATE449609T1 (de)
AU (1) AU781390B2 (de)
BR (1) BR0013778A (de)
CA (1) CA2382941C (de)
DE (1) DE60043391D1 (de)
EA (1) EA005066B1 (de)
EE (1) EE05262B1 (de)
ES (1) ES2335569T3 (de)
HK (1) HK1048075B (de)
IL (1) IL132312A0 (de)
MX (1) MXPA02002448A (de)
NO (1) NO325989B1 (de)
UA (1) UA74163C2 (de)
WO (1) WO2001018040A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355237B1 (en) * 1994-09-14 2002-03-12 Progenitor, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
US8633250B2 (en) * 2006-01-12 2014-01-21 Musc Foundation For Research Development Cell repair and regeneration by suramin and related polysulfonated napthylureas
US9592213B2 (en) 2009-06-17 2017-03-14 National University Corporation Kumamoto University Prophylactic and/or therapeutic agent for dysmenorrhea

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1731164A1 (de) * 1996-01-23 2006-12-13 Indevus Pharmaceuticals, Inc. Anwendungen des Obese-Gens und des Genprodukts zur Stimulierung der Haematopoietischen Entwicklung
IT1288388B1 (it) * 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
IL120733A0 (en) * 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
WO1999059614A1 (en) * 1998-05-20 1999-11-25 Yale University Modulation of angiogenesis and wound healing

Also Published As

Publication number Publication date
AU781390B2 (en) 2005-05-19
EE200200116A (et) 2003-04-15
WO2001018040A2 (en) 2001-03-15
HK1048075A1 (en) 2003-03-21
UA74163C2 (uk) 2005-11-15
CA2382941A1 (en) 2001-03-15
ES2335569T3 (es) 2010-03-30
NO325989B1 (no) 2008-09-01
NO20020920D0 (no) 2002-02-25
EP1210108B1 (de) 2009-11-25
IL132312A0 (en) 2001-03-19
HK1048075B (zh) 2005-07-29
CN1189479C (zh) 2005-02-16
WO2001018040A3 (en) 2001-06-14
CN1377277A (zh) 2002-10-30
EE05262B1 (et) 2010-02-15
KR100683362B1 (ko) 2007-02-15
JP2003508544A (ja) 2003-03-04
NO20020920L (no) 2002-05-03
ATE449609T1 (de) 2009-12-15
EA005066B1 (ru) 2004-10-28
EA200200331A1 (ru) 2002-08-29
EP1210108A2 (de) 2002-06-05
MXPA02002448A (es) 2002-07-30
AU6862000A (en) 2001-04-10
BR0013778A (pt) 2002-05-14
CA2382941C (en) 2011-08-16
KR20020040781A (ko) 2002-05-30
AR025494A1 (es) 2002-11-27

Similar Documents

Publication Publication Date Title
DE69927128T2 (de) Verwendung von topisch applizierbaren Gerinnungsmaterial
DE60027479D1 (de) Harzstruktur und ihre verwendung
NO20005253D0 (no) Fibergjenstander med luktabsorberende evne samt fremstilling derav
DE60040234D1 (de) Automatische erstellung von dokumenten mittels anordnungselement und inhaltselementen
DE60017894D1 (de) Diaminothiazole und ihre verwendung zur inhibierung von proteinkinasen
DE60039148D1 (de) Härtung von Bodenbeschichtungen mit Kurz- und Langwelligen UV-Strahlen
DE69909029D1 (de) Kosmetisches oder dermopharmazeutisches Pflaster
DE50012379D1 (de) Verwendung von nanoskaligen antischuppenwirkstoffen
DE69813211D1 (de) Fingerabdrucksensor mit filterung und energiesparende eigenschaften und zugehörigen verfahren
ATE302193T1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
PT1204663E (pt) Novos compostos espiro com actividade antagonista do neuropeptido y
DE59407397D1 (de) Verwendung von polymeren mit isolierten chromophoren als elektrolumineszenzmaterialien
DE60027927D1 (de) Harzstruktur und ihre verwendung
DE60032247D1 (de) Fluorchemisches oligomer und seine verwendung
DE69910152D1 (de) Verwendung von Phytosterol und/oder Phytostanolestern
DE59702603D1 (de) Teilkonjugierte polymere mit spirozentren und ihre verwendung als elektrolumineszenzmaterialien
DE60005829D1 (de) Zugespitzte bürstenborsten mit ton oder silika additiven und daraus hergestellte bürsten
DE60110453D1 (de) Weichlotwerkstoff und dessen verwendung in ein elektrisches oder elektronisches bauteil
DE60029289D1 (de) Bioabbaubare Polyesterharzzusammensetzung und seine Verwendung
DE59902868D1 (de) Verwendung von ectoin oder ectoin-derivaten in formulierungen
DE59507232D1 (de) Konjugierte Polymere mit Ansateilstrukturen und ihre Verwendung als Elektrolumineszenzmaterialien
DE60317639D1 (de) Zusammensetzungen enthaltend n-acyl-phosphatidyl-ethanolamin und/oder mischungen von n-acyl-ethanolaminen mit phosphatidinsäuren oder lysophosphatidinsäuren
DE69913923D1 (de) Drehkran und seiner Verwendung
DE60123113D1 (de) Pharmazeutische oder kosmetische zusammensetzung und verwendung eines pkc-inhibitors mit einem mmp-inhibitor zur hemmung der migration von langerhans-zellen
DE60043391D1 (de) Verwendung von leptin mit einem vegf hemmer und/oder angiogenese hemmer zur hemmung der proliferation endothelialer zellen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition